Abstract
Drug delivery to the eye is challenging for formulation scientists due to physiological barriers that separate the eye from the rest of the body. A variety of ocular disorders demand the development of optimal drug delivery systems for the administration of drugs and therapeutic agents that can overcome barriers that restrict drug bioavailability. SiRNA inhibits the expression of target genes and has immense potential as a biological tool for the therapeutic inhibition of disease causing genes; however, delivery of siRNA to ocular tissue is a challenge. Recent literature suggests that nanoplatforms show great promise in enhancing ophthalmic drug delivery. A drug delivery system involving nanoparticles and siRNA could surpass problems faced in ocular delivery with improved biodistribution and lower toxicity. This review covers recent research in the area of nanocarrier siRNA drug delivery for various ocular disorders.
Keywords: Ocular, drug delivery, siRNA, nanoplatforms, polymers, lipid nanoparticles, proteins, dendrimers.
Current Pharmaceutical Design
Title:Nanoplatforms for Delivery of siRNA to the Eye
Volume: 21 Issue: 31
Author(s): Manjir Sarma Kataki, Bibhuti Bhusan Kakoti, Melanie Jameson, Aum Solanki, Anjali Hirani and Yashwant Pathak
Affiliation:
Keywords: Ocular, drug delivery, siRNA, nanoplatforms, polymers, lipid nanoparticles, proteins, dendrimers.
Abstract: Drug delivery to the eye is challenging for formulation scientists due to physiological barriers that separate the eye from the rest of the body. A variety of ocular disorders demand the development of optimal drug delivery systems for the administration of drugs and therapeutic agents that can overcome barriers that restrict drug bioavailability. SiRNA inhibits the expression of target genes and has immense potential as a biological tool for the therapeutic inhibition of disease causing genes; however, delivery of siRNA to ocular tissue is a challenge. Recent literature suggests that nanoplatforms show great promise in enhancing ophthalmic drug delivery. A drug delivery system involving nanoparticles and siRNA could surpass problems faced in ocular delivery with improved biodistribution and lower toxicity. This review covers recent research in the area of nanocarrier siRNA drug delivery for various ocular disorders.
Export Options
About this article
Cite this article as:
Kataki Sarma Manjir, Kakoti Bhusan Bibhuti, Jameson Melanie, Solanki Aum, Hirani Anjali and Pathak Yashwant, Nanoplatforms for Delivery of siRNA to the Eye, Current Pharmaceutical Design 2015; 21 (31) . https://dx.doi.org/10.2174/138161282131151013191051
DOI https://dx.doi.org/10.2174/138161282131151013191051 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Plasminogen Activator Inhibitor-1 in Tumor Growth, Angiogenesis and Vascular Remodeling
Current Pharmaceutical Design Semaphorins and their Receptors in Stem and Cancer Cells
Current Medicinal Chemistry MicroRNA Therapeutics: The Emerging Anticancer Strategies
Recent Patents on Anti-Cancer Drug Discovery Choline-PET/CT in the Differential Diagnosis Between Cystic Glioblastoma and Intraparenchymal Hemorrhage
Current Radiopharmaceuticals Pharmacological Activation of p53 in Cancer Cells
Current Pharmaceutical Design Aquaporin and Blood Brain Barrier
Current Neuropharmacology Phosphonium Salt Displays Cytotoxic Effects Against Human Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Mechano-Regulation of Alternative Splicing
Current Genomics Biomedical Applications of Glycoconjugates
Mini-Reviews in Medicinal Chemistry Current Developments in Targeted Drug Delivery Systems for Glioma
Current Pharmaceutical Design A Review of Select Recent Patents on Novel Nanocarriers
Recent Patents on Drug Delivery & Formulation Contrast Functions of αA- and αB-Crystallins in Cancer Development
Current Molecular Medicine Cancer Chemoprevention by Targeting the Epigenome
Current Drug Targets Editorial [Hot Topic: New Approaches to Treating Cancer: Medicinal Chemistry and Therapeutic Potential (Guest Editor: David J. Weber)]
Current Topics in Medicinal Chemistry Bicycloheptylamine-Doxorubicin Conjugate: Synthesis and Anticancer Activities in σ2 Receptor-Expressing Cell Lines
Medicinal Chemistry Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets Sublethal Total Body Irradiation Leads to Early Cerebellar Damage and Oxidative Stress
Current Neurovascular Research Antigenic Differences Between Normal and Malignant Cells as a Basis for Treatment of Intracerebral Neoplasms Using a DNA-Based Vaccine
Current Genomics In Vitro Regulatory Effect of Epididymal Serpin CRES on Protease Activity of Proprotein Convertase PC4/PCSK4
Current Molecular Medicine Targeted Therapy for Glioblastoma: Lessons Learned and Future Directions
Current Cancer Therapy Reviews